Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics Collaboration to Explore Clinical Uses of Personal Genetics and TamoxifenStrategic Research Agreement • October 23rd, 2007 • Laboratory Corp of America Holdings • Services-medical laboratories
FRANKLIN LAKES, NJ and BURLINGTON, NC, October 22, 2007 – Medco Health Solutions Inc. (NYSE: MHS) and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced a strategic research agreement today to advance the field of pharmacogenomics, an emerging science integrating genetics and drug treatment that is leading the way toward personalized medicine. The research effort, which will be centered on tamoxifen, is the latest in a rapidly growing field of studies linking individual genetics to the safety and efficacy of specific prescription drugs. Genotyping for the study will be performed using the FDA-cleared Roche AmpliChip® CYP450 test.
RESEARCH PLAN Strategic Research Agreement - Single-ProjectStrategic Research Agreement • April 15th, 2012
JDRF Strategic Research Agreement Application ChecklistStrategic Research Agreement • June 21st, 2018
All of the Principal Investigators and key personnel are listed as salary line items and percent effort is indicated (even if they are not taking salary from the grant they must be listed as a line item and justified in the salary justification section)
JDRF Strategic Research Agreement Application ChecklistStrategic Research Agreement • June 10th, 2016
Applicant included accurate and complete information regarding all other sources of grant support from the main Principal Investigator (current and pending), including title, abstract, annual and total amount of the grant, inclusive funding period, and percent effort of the applicant.
STRATEGIC RESEARCH AGREEMENTStrategic Research Agreement • July 18th, 2019 • England and Wales
